Last updated on December 2019
Phase 1 Trial of MSC2490484A an Inhibitor of a DNA-dependent Protein Kinase in Combination With Radiotherapy
Brief description of study
MSC2490484A or M3814 is an investigational drug that is being evaluated for the treatment of subjects with locally advanced tumors. The main purposes of this study are to determine the safety, the tolerability and the efficacy of MSC2490484A in combination with radiotherapy and in combination with chemoradiotherapy (Radiotherapy + cisplatin).
Clinical Study Identifier: NCT02516813